Incyte Corp. Stock Underperforms Wednesday When Compared to Competitors Despite Daily Gains

Dow Jones
08/20

DJ Incyte Corp. Stock Underperforms Wednesday When Compared To Competitors Despite Daily Gains

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of Incyte Corp. $(INCY)$ advanced 4.05% to $128.47 Wednesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index rising 0.21% to 7,707.98 and the Dow Jones Industrial Average rising 0.22% to 53,463.05.

Incyte Corp. closed 3.11% short of its 52-week high of $132.60, which the company reached on July 28th.

The stock demonstrated a mixed performance when compared to some of its competitors Wednesday, as Alnylam Pharmaceuticals Inc. $(ALNY)$ rose 6.12% to $242.61, Bio-Techne Corp. (TECH) rose 0.36% to $72.48, and BioMarin Pharmaceutical Inc. $(BMRN)$ rose 3.49% to $69.33.

Trading volume (1.6 M) remained 347,803 below its 50-day average volume of 1.9 M.

Data source: Dow Jones Market Data, FactSet. Data compiled August 19, 2026.

 

應版權方要求,你需要登入查看該內容

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10